TD Asset Management Inc Decreases Stock Holdings in Moderna, Inc. $MRNA

Key Points

• TD Asset Management Inc has reduced its stake in Moderna, Inc. by 51.0%, selling 64,456 shares and leaving it with 61,813 shares valued at approximately $1.7 million.
• Several research firms maintain a cautious stance on Moderna's stock, with a range of price targets leading to an average consensus rating of "Hold" and a target price of $39.93 as of recent assessments.
• Moderna reported earnings of ($2.13) per share for the last quarter, surpassing estimates, but also marking a 41.1% revenue decline year-over-year, contributing to concerns about its financial health.

TD Asset Management Inc lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 51.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,813 shares of the company's stock after selling 64,456 shares during the quarter. TD Asset Management Inc's holdings in Moderna were worth $1,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. S Bank Fund Management Ltd purchased a new position in shares of Moderna during the first quarter valued at about $25,000. TD Private Client Wealth LLC increased its position in shares of Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company's stock valued at $26,000 after buying an additional 743 shares during the period. SVB Wealth LLC purchased a new position in shares of Moderna during the first quarter valued at about $28,000. CX Institutional increased its position in shares of Moderna by 1,129.8% during the second quarter. CX Institutional now owns 1,033 shares of the company's stock valued at $29,000 after buying an additional 949 shares during the period. Finally, Costello Asset Management INC purchased a new position in shares of Moderna during the first quarter valued at about $30,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on MRNA. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a research note on Monday. Citigroup began coverage on shares of Moderna in a research note on Friday, August 1st. They set a "neutral" rating and a $40.00 price objective on the stock. JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a research note on Friday, August 1st. Leerink Partners dropped their price objective on shares of Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a research note on Friday, August 22nd. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Moderna in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $39.93.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $27.49 on Wednesday. The firm's 50 day moving average price is $25.98 and its 200-day moving average price is $27.12. The company has a market cap of $10.74 billion, a PE ratio of -3.65 and a beta of 2.01. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $57.69.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business's revenue was down 41.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. On average, analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.